Immunology Seminar Series, Luke O’Neill
Immunology Seminar Series
February 7th at 14:00 – 15:00 (Finland time)
Luke O’Neill, Trinity College Dublin: Adventures in Immunometabolism Research
Host: Riitta Lahesmaa (email@example.com )
Registration latest February 6th at: https://link.webropolsurveys.com/S/C196B12841386EFF
Immunology seminar series is jointly organised by the Finnish Society for Immunology, InFLAMES Flagship and Turku Bioscience. For further information contact Anne Lahdenperä (firstname.lastname@example.org) or Riitta Lahesmaa (email@example.com), University of Turku.
Luke O’Neill is Professor of Biochemistry in the School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute at Trinity College Dublin, Ireland. He is a world expert on innate immunity and inflammation. His main research interests include Toll-like receptors, Inflammasomes and Immunometabolism. He is listed by Thompson Reuters/ Clarivates in the top 1% of immunologists in the world, based on citations per paper. Professor O’Neill is co-founder of Sitryx, which aims to develop new medicines for inflammatory diseases. Another company he co-founded, Inflazome was recently acquired by Roche.
He was awarded the Royal Dublin Society / Irish Times Boyle Medal for scientific excellence, the Royal Irish Academy Gold Medal for Life Sciences, The Society for Leukocyte Biology (SLB) Dolph O. Adams award, the European Federation of Immunology Societies Medal, the Milstein Award of the International Cytokine and Interferon Society and the Landsteiner Award from the Austrian Academy of Sciences. He is a member of the Royal Irish Academy, EMBO (European Molecular Biology Organisation) and a Fellow of the Royal Society.
Ryan DG, O’Neill LAJ Krebs Cycle Reborn in Macrophage Immunometabolism. Annu Rev Immunol. 2020 Jan 27. doi: 10.1146/annurev-immunol-081619-104850
O’Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol. 2020 Jun;20(6):335-337. doi: 10.1038/s41577-020-0337-y.
Hooftman A, Angiari S, Hester S, Corcoran SE, Runtsch MC, Ling C, Ruzek MC, Slivka PF, McGettrick AF, Banahan K, Hughes MM, Irvine AD, Fischer R, O’Neill LAJ. The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation. Cell Metab. 2020 Sep 1;32(3):468-478.e7. doi: 10.1016/j.cmet.2020.07.016.
Runtsch MC, Angiari S, Hooftman A, Wadhwa R, Zhang Y, Zheng Y, Spina JS, Ruzek MC, Argiriadi MA, McGettrick AF, Mendez RS, Zotta A, Peace CG, Walsh A, Chirillo R, Hams E, Fallon PG, Jayamaran R, Dua K, Brown AC, Kim RY, Horvat JC, Hansbro PM, Wang C, O’Neill LAJ.Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages. Cell Metab. 2022 Mar 1;34(3):487-501.e8. doi: 10.1016/j.cmet.2022.02.002.
Hooftman A, O’Neill LAJ.Nanoparticle asymmetry shapes an immune response. Nature. 2022 Jan;601(7893):323-325. doi: 10.1038/d41586-021-03806-7.